Have a personal or library account? Click to login

Developing an algorithm for the management of Renal Cell Carcinoma: focus on metastatic disease

Forum of Clinical Oncology
Volume 8 (2017): Issue 1 (June 2017)
By:
Open Access
|Jun 2017

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin2013 Jan;63(1):11-30.23335087
    Search in Google ScholarBack to article
  2. Novara G, Ficarra V, Antonelli A, Artibani W, Bertini R, Carini M, et al. Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? Eur Urol2010 Oct;58(4):588-95.10.1016/j.eururo.2010.07.006
    Open DOISearch in Google ScholarBack to article
  3. Fujioka T, Obara W, Committee for Establishment of the Clinical Practice Guideline for the Management of Renal Cell C, the Japanese Urological A. Evidence-based clinical practice guideline for renal cell carcinoma: the Japanese Urological Association 2011 update. Int J Urol2012 Jun;19(6):496-503.
    Search in Google ScholarBack to article
  4. Bazarbashi S, Alkhateeb S, Abusamra A, Rabah D, Alotaibi M, Almansour M, et al. Saudi oncology society and Saudi urology association combined clinical management guidelines for renal cell carcinoma. Urol Ann2014 Oct;6(4):286-9.10.4103/0974-7796.14097425371602
    Open DOISearch in Google ScholarBack to article
  5. Bellmunt J, Puente J, Garcia de Muro J, Lainez N, Rodriguez C, Duran I, et al. SEOM clinical guidelines for the treatment of renal cell carcinoma. Clin Transl Oncol2014 Dec;16(12):1043-50.10.1007/s12094-014-1219-125274276
    Open DOISearch in Google ScholarBack to article
  6. Ljungberg B, Gudmundsson E, Christensen S, Lundstam S, Swedish Kidney Cancer Quality Register G. Practice patterns for the surgical treatment of T1 renal cell carcinoma: a nationwide population-based register study. Scand J Urol2014 Oct;48(5):445-52.10.3109/21681805.2014.898686
    Open DOISearch in Google ScholarBack to article
  7. Campbell L, Nuttall R, Griffiths D, Gumbleton M. Activated extracellular signal-regulated kinase is an independent prognostic factor in clinically confined renal cell carcinoma. Cancer2009 Aug 01;115(15):3457-67.10.1002/cncr.2438919526593
    Open DOISearch in Google ScholarBack to article
  8. Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, et al. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw2009 Jun;7(6):618-30.1955558410.6004/jnccn.2009.0043
    Open DOISearch in Google ScholarBack to article
  9. Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol2016 Sep;27(suppl 5):v58-v68.
    Search in Google ScholarBack to article
  10. Zekri J, Dreosti LM, Ghosn M, Hamada E, Jaloudi M, Khorshid O, et al. Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvement. J Multidiscip Healthc2015;8:335-44.26251610
    Search in Google ScholarBack to article
  11. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, et al. Kidney cancer, version 3.2015. J Natl Compr Canc Netw2015 Feb;13(2):151-9.2569160610.6004/jnccn.2015.0022
    Open DOISearch in Google ScholarBack to article
  12. Zagouri F, Peroukidis S, Tzannis K, Kouloulias V, Bamias A, Hellenic Genito-Urinary Cancer G. Current clinical practice guidelines on chemotherapy and radiotherapy for the treatment of non-metastatic muscle-invasive urothelial cancer: a systematic review and critical evaluation by the Hellenic Genito-Urinary Cancer Group (HGUCG). Crit Rev Oncol Hematol2015 Jan;93(1):36-49.
    Search in Google ScholarBack to article
  13. Bamias A, Escudier B, Sternberg CN, Zagouri F, Dellis A, Djavan B, et al. Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation. Oncologist2017 Jun;22(6):667-79.10.1634/theoncologist.2016-043528592625
    Open DOISearch in Google ScholarBack to article
  14. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol2016 Jul;70(1):93-105.2693555910.1016/j.eururo.2016.02.029
    Open DOISearch in Google ScholarBack to article
  15. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol2010 Jun;17(6):1471-4.10.1245/s10434-010-0985-420180029
    Open DOISearch in Google ScholarBack to article
  16. Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol2001 Mar 15;19(6):1649-57.10.1200/JCO.2001.19.6.164911250993
    Open DOISearch in Google ScholarBack to article
  17. Rini B, Goddard A, Knezevic D, Maddala T, Zhou M, Aydin H, et al. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. Lancet Oncol2015 Jun;16(6):676-85.2597959510.1016/S1470-2045(15)70167-1
    Open DOISearch in Google ScholarBack to article
  18. Margulis V, Master VA, Cost NG, Leibovich BC, Joniau S, Kuczyk M, et al. International consultation on urologic diseases and the European Association of Urology international consultation on locally advanced renal cell carcinoma. Eur Urol2011 Oct;60(4):673-83.2175253310.1016/j.eururo.2011.06.042
    Open DOISearch in Google ScholarBack to article
  19. Aitchison M, Bray CA, Van Poppel H, Sylvester R, Graham J, Innes C, et al. Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial. Eur J Cancer2014 Jan;50(1):70-7.24074763
    Search in Google ScholarBack to article
  20. Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet2016 May 14;387(10032):2008-16.2696909010.1016/S0140-6736(16)00559-6
    Open DOISearch in Google ScholarBack to article
  21. Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, et al. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. N Engl J Med2016 Dec 08;375(23):2246-54.10.1056/NEJMoa161140627718781
    Open DOISearch in Google ScholarBack to article
  22. Robert J. Motzer NBH, Frede Donskov, Marine Gross-Goupil, Sergei Varlamov, Evgeny Kopyltsov, Jae-Lyun Lee, Bohuslav Melichar, Brian I. Rini, Toni K. Choueiri, Milada Zemanova, Lori A Wood, Dirk Fahlenkamp, Martin Neil Reaume, Arnulf Stenzl, Weichao Bao, Paola Aimone, Christian Doehn, Paul Russo, Cora N. Sternberg. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT). ASCO, J Clin Oncol 35, 2017 (suppl; abstr 4507)2017.
    Search in Google ScholarBack to article
  23. Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, et al. Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma. Eur Urol2017 May;71(5):719-22.2798636910.1016/j.eururo.2016.11.034
    Open DOISearch in Google ScholarBack to article
  24. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol2004 Mar;171(3):1071-6.10.1097/01.ju.0000110610.61545.ae14767273
    Open DOISearch in Google ScholarBack to article
  25. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet2007 Dec 22;370(9605):2103-11.10.1016/S0140-6736(07)61904-718156031
    Open DOISearch in Google ScholarBack to article
  26. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med2007 Jan 11;356(2):115-24.1721552910.1056/NEJMoa065044
    Open DOISearch in Google ScholarBack to article
  27. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol2010 Feb 20;28(6):1061-8.10.1200/JCO.2009.23.976420100962
    Open DOISearch in Google ScholarBack to article
  28. Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, et al. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol2017 Feb 20;35(6):591-7.2819981810.1200/JCO.2016.70.7398
    Open DOISearch in Google ScholarBack to article
  29. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med2007 May 31;356(22):2271-81.1753808610.1056/NEJMoa066838
    Open DOISearch in Google ScholarBack to article
  30. Hess G, Borker R, Fonseca E. Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting. Clin Genitourin Cancer2013 Jun;11(2):161-7.10.1016/j.clgc.2012.10.003
    Open DOISearch in Google ScholarBack to article
  31. Ko JJ, Choueiri TK, Rini BI, Lee JL, Kroeger N, Srinivas S, et al. First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. Br J Cancer2014 Apr 15;110(8):1917-22.2469142510.1038/bjc.2014.25
    Open DOISearch in Google ScholarBack to article
  32. Escudier B, Albiges L, Blesius A, Loriot Y, Massard C, Fizazi K. How to select targeted therapy in renal cell cancer. Ann Oncol2010 Oct;21 Suppl 7:vii59-62.
    Search in Google ScholarBack to article
  33. Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med2015 Nov 05;373(19):1814-23.2640615010.1056/NEJMoa1510016
    Open DOISearch in Google ScholarBack to article
  34. Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol2016 Jul;17(7):917-27.10.1016/S1470-2045(16)30107-327279544
    Open DOISearch in Google ScholarBack to article
  35. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med2015 Nov 05;373(19):1803-13.2640614810.1056/NEJMoa1510665
    Open DOISearch in Google ScholarBack to article
  36. Powles T, Staehler M, Ljungberg B, Bensalah K, Canfield SE, Dabestani S, et al. Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy. Eur Urol2016 Jan;69(1):4-6.2650831210.1016/j.eururo.2015.10.017
    Open DOISearch in Google ScholarBack to article
  37. Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Szczylik C, Zolnierek J, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol2014 Mar;15(3):286-96.10.1016/S1470-2045(14)70030-024556040
    Open DOISearch in Google ScholarBack to article
  38. Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol2014 Sep 01;32(25):2765-72.2504933010.1200/JCO.2013.54.6911
    Open DOISearch in Google ScholarBack to article
  39. Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol2016 Mar;17(3):378-88.10.1016/S1470-2045(15)00515-X
    Open DOISearch in Google ScholarBack to article
  40. Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, et al. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol2016 May;69(5):866-74.10.1016/j.eururo.2015.10.04926626617
    Open DOISearch in Google ScholarBack to article
DOI: https://doi.org/10.1515/fco-2015-0025 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Journal RSS Feed
Language: English
Page range: 15 - 21
Submitted on: Aug 8, 2017
Accepted on: Aug 24, 2017
Published on: Jun 30, 2017
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 times per year
Keywords:
Renal cell carcinoma,
Metastatic Disease,
Therapeutic algorithm
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology

© 2017 Anastasios Kyriazoglou, Ioannis Dimitriadis, Aristotelis Bamias, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 8 (2017): Issue 1 (June 2017)Next article